Avalon granted Notice of Allowance for CAR-T and CAR-NK cell technology in China

Avalon (ALBT) GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent application AVAR1901CN. This patent, co-developed with Hong Kong-based Arbele, marks a milestone in the advancement of chimeric antigen receptor-based therapies. It extends Avalon’s global intellectual property footprint to China, beyond the U.S., and additional territories under the Patent Cooperation Treaty. The AVAR1901CN patent focuses on technology designed to enhance the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer cells.